Evidence map›Paper›PMID 8549287›Full record

ReviewDrugs1995

Fluoroquinolone toxicities. An update.

P S Lietman

Abstract readReview
PubMed Publisher
In one paragraph

Review in Drugs, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 88 citations in OpenAlex.

  1. Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2003
    Trial
  2. Trial
  3. Early postoperative fluoroquinolone use is associated with an increased revision rate after arthroscopic rotator cuff repair.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2017
    Article
  4. Article
  5. Systemic use of fluoroquinolone in children.Korean journal of pediatrics · 2013
    Article
  6. Article
  7. Article
  8. Safety of fluoroquinolones: An update.The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses · 2002
    Article
  9. Review
  10. Article
  11. Review
  12. Quinolones: which generation for which microbe?The Western journal of medicine · 1999
    Review
  13. The new fluoroquinolones: A critical review.The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses · 1999
    Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

P S LietmanDivision of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main types of adverse effects associated with quinolones are uncommon and reversible and vary in frequency among different agents. Phototoxicity appears more frequent with lomefloxacin than with some other quinolones. Three mechanisms have been proposed to explain the neurotoxic effects, including rare proconvulsant activity, associated with quinolone therapy. Arthropathy remains a dilemma for paediatricians deciding whether to use quinolones in growing children. Importantly, the experience with temafloxacin, which has now been withdrawn from the market, emphasises the need for thorough postmarketing surveillance. Nonetheless, it should be remembered that the fluoroquinolones as a group are effective and very well tolerated antimicrobial drugs.

Indexed as

FluoroquinolonesAnti-Infective AgentsDermatitis, PhototoxicHumansJoint DiseasesNervous System DiseasesQuinolonesAnti-Infective AgentsFluoroquinolonesQuinolonestemafloxacin

Identifiers

PMID8549287
OpenAlexW2021981777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.